Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Trial Profile

Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Uveal melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2016 Planned number of patients changed from 30 to 10.
    • 10 May 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2019.
    • 26 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top